Study of Anlotinib in Patients With Soft Tissue Sarcoma（STS）(ALTER0203)
Compare the effects and safety of Anlotinib with placebo in patients with soft tissue sarcoma.
Soft Tissue Sarcoma
DRUG: Anlotinib|DRUG: Placebo
Progress free survival (PFS), up to 24 months
Overall Survival (OS), up to 24 months|Objective Response Rate (ORR), up to 24 months|Disease Control Rate (DCR), up to 24 months
Compare the effects and safety of Anlotinib with placebo in patients with soft tissue sarcoma.